Navigation Links
Antibody-guided drug shows encouraging activity in metastatic breast cancer
Date:12/12/2009

SAN ANTONIO, TXA new antibody-drug compound shrank or halted the growth of metastatic breast tumors in almost half of a group of patients whose HER2-positive cancer had become resistant to standard therapies, according to early data from a multicenter Phase 2 clinical trial led by a Dana-Farber Cancer Institute researcher.

The findings will be presented at the 32nd annual CTRC-AACR San Antonio Breast Cancer Symposium on Saturday, Dec. 12 (Abstract 710, Henry B. Gonzalez Convention Center, Exhibit Hall B, 7-9 a.m. CT).

Ian Krop, MD, PhD, principal investigator of the study, will report that the hybrid agent, called T-DM1, shrank tumors by 30 percent or more in 40 percent of women with confirmed HER2-positive cancers. Another 13 percent had stable disease for at least six months, for a total clinical benefit rate of approximately 53 percent. The median time before the disease progressed was 7.3 months, including both responders and non-responders. Patients received T-DM1 as long as it was effective and well-tolerated. A total of 110 women were enrolled in the study.

T-DM1 is comprised of the cell-killing drug DM1 and is chemically linked to the monoclonal antibody trastuzumab, which selectively binds to the HER2 growth signal receptor, which is highly overexpressed in HER2-positive breast tumors. Approximately 20 percent of breast cancers are HER2-postive.

Trastuzumab, developed by Genentech and sold under the name Herceptin, has markedly improved the treatment of HER2-positive cancer, but resistance to trastuzumab is a significant problem.

"The antibody binds to the HER2 protein on tumor cells and delivers the drug (DM1) selectively to them but not to normal cells," Krop explained. "This allows us to deliver high doses of the chemotherapy directly to tumor cells. And at the same time, the antibody continues to block the HER2 growth signals."

Krop said that one of the unique features of the study is that it is the first to address a population of women with metastatic HER2-positive breast cancer whose disease had progressed despite treatment with all of the FDA-approved drugs for this disease (trastuzumab, lapatinib and several chemotherapy agents).

On average, the women had metastatic breast cancer for three years and previously received seven different drugs for their cancer.

Although patients experienced side effects that included nausea, fatigue and lowered platelet counts, these effects were typically mild and the drug in general was well-tolerated, said Krop.

In addition to the current study, T-DM1 is being tested in larger Phase 3 trials comparing its effectiveness with that of other combined therapies.


'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. New study shows promise in reducing surgical risks associated with surgical bleeding
2. New research shows how chronic stress worsens neurodegenerative disease course
3. Embryonic Human Stem Cells May Help Repair Heart Muscle, Lab Study Shows
4. Circulating fats kill transplanted pancreas cells, study shows
5. New Heart Pump Shows Promise in Trial
6. Novel 3-D cell culture model shows selective tumour uptake of nanoparticles
7. New Survey Shows Americans are Still Concerned About Food Safety, Yet Still Not Smart About What They Like to Eat
8. Australian-led international study shows blood pressure drugs cut death rate in type 2 diabetes
9. Amid Improving Life Expectancy Rates, Risk of Premature Death is Still Significant for Americans, New Study Shows
10. Avocados may help prevent oral cancer, OSU study shows
11. New Poll Shows Public Distrusts Flawed Healthcare Approach Favored by Governor and Speaker in AB 8
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... STAMFORD, CONNECTICUT (PRWEB) , ... April 29, 2016 , ... ... 5K Run/Walk” at Cove Island Park on Sunday, with sunny skies, a light breeze ... event, raising nearly $33,000. , The 5k Run and Walk and 1-mile ...
(Date:4/29/2016)... ... 29, 2016 , ... Spine Team Texas, a comprehensive spine physician group specializing ... their physicians has been invited to be a featured speaker at the Texas Society ... on April 30, 2016. , Dr. R. Scott McPherson, a physical medicine and ...
(Date:4/29/2016)... ... April 29, 2016 , ... World ... the Gyrociser, an exercise invention which aids in proper muscle development. , "The ... CEO and Creative Director of World Patent Marketing. "Globalization has threatened the future ...
(Date:4/29/2016)... ... 2016 , ... Dr. Robert Mondavi, one of the dentists in Torrance ... a fast-growing field as more patients are discovering the many different ways they can ... options currently available to them and which ones might work for their smiles. ...
(Date:4/29/2016)... ... 29, 2016 , ... For those who skip meals occasionally (which is pretty ... among the many new lifestyle diet tips offered by nutritionists Pam Bonney and Priya ... Water® radio show. Bonny and Lawrence noted that because proper nutrition, including water, provides ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016 ... Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen ... bekannt, dass neue Führungskräfte zum Team Sicherheit ... die vielfältige Erfahrungen mitbringen.  Dies wird die ...
(Date:4/28/2016)... -- , Net Sales of $1.90 billion represent an ... year period, and an increase of 1.2% on an adjusted ... the first quarter were $0.52 reported, a decrease of 47.5% ... of 29.9% over the prior year period , The ... 2016 Zimmer Biomet Holdings, Inc. (NYSE and SIX: ...
(Date:4/28/2016)...   Acsis , a leading provider of supply ... research and advisory firm IDC has named it a ... Pharmaceutical Track and Trace Software 2016 Vendor Assessment (doc ... of the capabilities and business strategies of 10 vendors ... Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
Breaking Medicine Technology: